I would like to make certain comments on recent article by Kim, et al. [1] on growth facet of Crohn’s disease [1]. Azathioprine was started at the outset of treatment itself that in a group had mild to moderate disease though it is recommended only in those with severe disease or those with frequent relapses [2]. Also, authors have not mentioned the frequency of disease flare-up in follow-up and their management. Since present study takes into account growth parameters as major outcome, inclusion of nutritional intake assessment in all study groups at 0, 2, 12 month time interval and their comparison would have added to results of study. Finally, there is a significant difference noted between increment in weight Z scores of steroid and azathioprine group at 2 months however in both groups steroids were used in induction phase and azathioprine effect is generally seen after 3 month of start. For such a difference no plausible explanation is given in text.

Editor’s Note: Authors of the original paper did not respond to this letter.

1. Kim MK, Lee WY, Choi KE, Yon Ho Choe. Effect of Infliximab ‘Top-down’ Therapy on Weight Gain in Pediatric Crohn’s Disease. Indian Pediatr. 2012;49: 979-82.